This trial is complete, and early published reports highlight acceptable safety as a monotherapy with modest clinical activity, though no data were given for the use in combination with azacitidine.277 CPI0610 is another BET inhibitor that demonstrated a BET-driven reduction in MYC gene expression and AML tumor growth inhibition in a xenograft study278 and is currently under evaluation in multiple phase I clinical trials in lymphoma and MM, and a phase II trial that is recruiting for acute leukemia, MDS/MPN, and myelofibrosis (NCT02157636, NCT01949883, NCT02158858). Here, MYC is linked to lymphoma.